EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis

Ai Kuzumi, Satoshi Ebata, Takemichi Fukasawa, Kazuki M Matsuda, Hirohito Kotani, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki

JAMA Dermatology · 01.04.2023 · 159 (4) · 374

DOI: 10.1001/jamadermatol.2022.6340 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.04.2023. Verfasst von Ai Kuzumi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Scleroderma, Systemic. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Rituximab is emerging as a promising therapeutic option for systemic sclerosis (SSc), but its long-term outcomes and response markers are unknown.

Objective

To evaluate the long-term outcomes after rituximab treatment for SSc and identify potential response markers. Design, Setting, and Participants In this single-center cohort study, patients with SSc who continued to receive rituximab after the DESIRES trial were analyzed with a median follow-up of 96 weeks. Among the 43 patients who completed the DESIRES trial, 31 continued to receive rituximab, of which 29 with complete data were included in this study. Exposures Rituximab treatment. Main Outcomes and Measures A post hoc analysis of the clinical and laboratory data.

Results

In 29 patients with SSc (27 female [93%]; median [IQR] age, 48 [35-45] years), significant improvement in modified Rodnan skin score (MRSS) and percentage of predicted forced vital capacity (FVC%) were observed after 1 (median [IQR] change in MRSS, −7 [−8.5 to −4]; P < .001) and 3 (median [IQR] change in FVC% predicted, 1.85 [0.13-5.68]; P < .001) courses of rituximab, respectively, both of which were sustained during follow-up. High responders (MRSS improvement of ≥9; n = 16) experienced a greater decrease in serum levels of IgG (median [IQR] change in IgG, −125 [−207 to −83] vs 7 [−120 to 43]; P = .008) and IgA (median [IQR] change in IgA, −45 [−96 to −32] vs −11 [−20 to 3]; P < .001) compared with low responders (MRSS improvement of ≤8; n = 13). In particular, decrease in serum IgA levels significantly correlated with the improvement in MRSS ( r = 0.64; P < .001). At the last follow-up, low IgM, low IgA, and low IgG was observed in 7, 1, and 1 patient, respectively, of which low IgM was associated with greater improvement in FVC% predicted (median [IQR] change in FVC% predicted, 7.2 [3.8-8.9] vs 3.6 [1.4-6.2]; P = .003). Conclusions and Relevance In this cohort study, rituximab treatment was associated with significantly improved skin and lung fibrosis in SSc in a long-term follow-up. Decrease in serum immunoglobulins was associated with greater clinical response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicFemaleHumansMiddle AgedCohort StudiesFollow-Up StudiesImmunoglobulin AImmunoglobulin GImmunoglobulin MRituximabSkinTreatment Outcome

Substanzen

Immunoglobulin AImmunoglobulin GImmunoglobulin MRituximab

Autor:innen und Institutionen

  • Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Zitieren

APA

Kuzumi, A., Ebata, S., Fukasawa, T., Matsuda, K. M., Kotani, H., Yoshizaki-Ogawa, A., Sato, S., & Yoshizaki, A. (2023). Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis. JAMA Dermatology, 159(4), 374. https://doi.org/10.1001/jamadermatol.2022.6340

Vancouver

Kuzumi A, Ebata S, Fukasawa T, Matsuda KM, Kotani H, Yoshizaki-Ogawa A, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis. JAMA Dermatology. 2023;159(4):374. doi:10.1001/jamadermatol.2022.6340

BibTeX
@article{Kuzumi2023,
  author = {Kuzumi, Ai and Ebata, Satoshi and Fukasawa, Takemichi and Matsuda, Kazuki M and Kotani, Hirohito and Yoshizaki-Ogawa, Asako and Sato, Shinichi and Yoshizaki, Ayumi},
  title = {Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis},
  journal = {JAMA Dermatology},
  year = {2023},
  volume = {159},
  number = {4},
  pages = {374},
  doi = {10.1001/jamadermatol.2022.6340}
}
Kostenlos starten →